InvestorsHub Logo
Followers 48
Posts 5518
Boards Moderated 0
Alias Born 09/04/2009

Re: JRoon71 post# 375484

Monday, 04/25/2022 4:32:54 PM

Monday, April 25, 2022 4:32:54 PM

Post# of 425931
J, REDUCE-IT patients were in the trial for an average of 4.9 years and did not stop for efficacy at interim checkpoint 1 and interim checkpoint 2. However, you expect convincing curve separation within one year with much fewer patients in each arm in MITIGATE than in REDUCE-IT. What's the logic?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News